Mylan Laboratories Limited has received a risk category 1 ranking from the WHO Expert Review Panel for its generic injectable, medroxyprogesterone acetate depot 150mg/ml.
News & Events
- We Need More Pharmaceutical R&D to Improve Maternal Health
- WHO Prequalifies a 2nd generic DMPA product with Concept Foundation support
- WHO has just prequalified a combination mifepristone-misoprostol (combipack) for medical abortion
- WHO has just prequalified a combination mifepristone-misoprostol (combipack) for medical abortion
- A third quality assured, generic DMPA-IM product available for procurement